Futura Medical PLC Futura Medical plc Board Appointment (4120O)
08 Ottobre 2021 - 08:00AM
UK Regulatory
TIDMFUM
RNS Number : 4120O
Futura Medical PLC
08 October 2021
8 Oct 2021
Futura Medical plc
("Futura" or the "Company")
Board Appointment
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, is pleased to announce
that Jeff Needham has been appointed to the Board as a
non-executive director with immediate effect.
Jeff brings a wealth of knowledge and experience to the Board
having been at Perrigo Company plc, the US-based manufacturer and
marketer of consumer healthcare products, for 36 years, and a board
director of the Consumer Healthcare Products Association for 12
years. Whilst at Perrigo, Jeff was responsible for the consumer
self-care businesses in the Americas, that included Perrigo's US
OTC Drug business, Nutritionals, Oral Care and its businesses in
Mexico and Canada. Jeff's focus was on the development and
long-term strategic direction of the business, including marketing,
sales, new product pipeline development, business development and
scientific affairs.
Commenting on the appointment, James Barder, Chief Executive
Officer of the Company, said: "We are delighted to welcome Jeff, a
seasoned and highly respected industry leader, to the Board of
Directors. His unparalleled management, strategic and corporate
expertise, especially in Consumer Health, OTC and the USA
underscores our ambition and focus on building a global brand to
deliver MED3000, our breakthrough treatment for erectile
dysfunction to sufferers as a therapy option without the need for a
doctor's prescription."
In accordance with Schedule 2(g) of the AIM Rules, Jeffrey
Robert Needham (aged 65) holds or has held directorships of the
following companies:
Current Directorships Past Directorships held in the past
five years
McKee Foods Corporation Consumer Healthcare Products Association
Perrigo Laboratories India Private
Limited
Perrigo UK Acquisition Limited
Meishangsha Jinshi Pet Products Trade
(Shanghai) Co Ltd
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Richard Lindley/ Euan Brown/ Kane Collings
Tel: +44 (0) 203 100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 922 0891
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction (ED) through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application. MED3000 is CE marked in Europe
and the UK as a clinically proven topical treatment for adult men
with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEDLFBFBLLFBV
(END) Dow Jones Newswires
October 08, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Mar 2023 a Mar 2024